"Designing Growth Strategies is in our DNA"

Biopharmaceuticals Market Size, Share and Analysis by Type (Immunomodulators {Monoclonal Antibodies, Interferons, Cytokines, Others}, Vaccines {Recombinant/ Conjugate/ Subunit, Live Attenuated, Inactivated, Toxoid}, Enzymes {Hydrolases, Lyases, Oxidoreductases, and Others}, Hormones {Human Growth Hormone, Insulin, Thyroid Stimulating Hormone, and Others}, and Others), By Application (Cardiology, Oncology, Respiratory, Immunology, Neurology, and Others), and Regional Forecast, 2023-2030

Region : Global | Report ID: FBI106928 | Status : Ongoing



Biopharmaceuticals consist of sugars, proteins, nucleic acids, living cells, or tissues that are extracted or semi-synthetically produced from natural sources such as humans, animals, and microorganisms used for the treatment of various diseases such as cancer, diabetes, respiratory disorders, hormonal disorders, etc. The biopharmaceuticals market is growing due to rising demand owing to its efficiency and ability to treat the disease with minimal side effects. Moreover, the prevalence of chronic diseases is at the rise due to the increasing geriatric population is contributing to the rising demand of biopharmaceutical drugs in the market.

  • According to a United Nations report, the world ageing population in 2019 was 702.9 million and is expected to grow by 120% by 2050 i.e. 1,548.9 million.

Moreover, increasing investments in research and developments for the introduction of new drugs, supporting government regulations are some of the major factors responsible for the market growth.

  • In June 2022, AbbVie Inc. received U.S. approval as the first and only specific Interleukin-23 to treat moderate to severe Crohn’s disease in adults. 

  • In March 2022, AstraZeneca received U.S. FDA approval for Lynparza for the treatment of BRCA mutation early-stage breast cancer.  

Impact of COVID-19 on the Biopharmaceutical Market

The COVID-19 pandemic is expected to boost the growth of the global biopharmaceuticals market during the forecast period due to increasing partnerships of key players for the research and development of drugs and vaccines owing to rising demand of the vaccines and monoclonal antibodies for the treatment and prevention of the COVID-19 infection.

  • In June 2022, Pfizer Inc., and BioNTech SE., announced positive results for safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates i.e. monovalent and bivalent.

  • In June 2022, Pfizer Inc. collaborated with BioNTech SE., to supply the Omicron-adapted COVID-19 vaccines, to the U.S. government.

Key Insights

  • Prevalence of key Diseases - Key Countries/ Regions.

  • New product Launches - key Players.

  • Pipeline Analysis - key Players.

  • Regulatory Scenario.

  • Key industry Developments - Partnerships, Mergers & Acquisitions.

  • Impact of COVID-19 on Biopharmaceuticals Market.

Analysis by Type

The monoclonal antibody segment is expected to drive the market due to various applications used in treatment of oncology, respiratory disorders, viral infections etc. Moreover, the key players are collaborating with each other to manufacture and sell drugs in the market to cater to the rising demand for the treatment of various key diseases.

  • In May 2022, AstraZeneca entered into an agreement with RQ Biotechnology Ltd to acquire an exclusive license to develop, manufacture, and sell monoclonal antibodies against SARS-CoV-2.

Analysis by Application

Oncology segment is expected to drive the market due to the rising prevalence of cancer globally and the growing demand of biopharma products for the treatment of cancers. Along with this, to cater to the rising demand the key players are focusing on partnerships for the research and development of new drugs and launching new products in the market.

  • In March 2022, Bristol-Myers Squibb Company acquired Turning Point Therapeutics, Inc., to launch Repotrectinib, an NTRK Inhibitor for the treatment of non-small cell lung cancer.

Analysis by End User

The hospital segment is expected to drive the market. Factors influencing the growth of hospital and specialty clinics include the prescription pattern of the drugs such as biologics for the treatment of disease. As the cost of these drugs is very high and the easy reimbursement policy for these drugs is driving the growth of this segment.

Regional Analysis

To gain extensive insights into the market, Request for Customization

North America is expected to account for the maximum share of the biopharmaceutical market. The rising number of biosimilar product launches and FDA approvals from regulatory authorities, due to increasing demand for the treatment of various diseases, is fueling the biopharmaceutical market in the U.S.

  • For instance, Pfizer launched 3 products in 2020. Moreover, in 2021, the U.S. enrolled 90 biosimilar products in the FDA’s biosimilar program.

  • In March 2022, Pfizer Inc. announced its acquisition of Arena Pharmaceuticals, a clinical-stage company, to offer potential therapies for a broader number of patients with immune-inflammatory diseases.

Key Players Covered

The report will include the profiles of key players such as Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Merck & Co., AstraZeneca, Bristol-Myers Squibb Company, and Novo Nordisk A/S, GSK plc.


By Type

By Application

By Geography

  • Immunomodulators

    • Monoclonal antibodies

    • Cytokines

    • Interferons

    • Others

  • Enzymes

    • Hyrdolases

    • Lyases

    • Oxidoreductases

    • Others

  • Vaccines

    • Recombinant Vaccines / Conjugate / Subunit

    • Inactivated

    • Live Attenuated

    • Toxiod

  • Hormones

    • Human Growth Hormones

    • Insulin

    • Thyroid Stimulating Hormone

    • Others

  • Others

  • Cardiology

  • Oncology

  • Respiratory

  • Immunology

  • Neurology

  • Others

  • North America (U.S. and Canada)

  • Europe (Germany, U.K., France, Italy, Spain, and Rest of Europe)

  • Asia Pacific (China, India, Australia, and Rest of Asia Pacific)

  • Middle East & Africa (UAE, South Africa, and Rest of the MEA)

  • Latin America (Brazil, Mexico, and Rest of LATAM  

Key Industry Developments

  • In June 2022, Bristol-Myers Squibb Company received U.S. FDA approval for CAR T Cell Therapy Breyanzi for the treatment of patients with large B-cell lymphoma, including diffuse large B-cell lymphoma.

  • In March 2022, Novo Nordisk A/S received U.S. FDA approval for Ozempic for the treatment of type 2 diabetes.

  • In Jan 2022, AbbVie Inc. received U.S. FDA approval for RINVOQ (upadacitinib) for the treatment of moderate to severe atopic dermatitis.

  • In March 2022, Merck announced that U.S. FDA has approved KEYTRDUSA, Merck’s anti- PD-1 therapy as a single agent used for the treatment of the endometrial carcinoma

  • Ongoing
  • 2022
  • 2019-2021


  • $4850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients


Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.